Ascentage Pharma Group International
AAPGVOTCHealthcare
$17.38
+$0.13(+0.75%)
Market Cap$127308500
P/E Ratio—
52W High$18.0
52W Low$16.5
Ascentage Pharma Group International (AAPGV) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · AAPGV · as of 2026-06-15
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2024-12 | 2023-12 | 2022-12 | 2021-12 | 2020-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($0.40B) | ($0.93B) | ($0.89B) | ($0.83B) | ($0.68B) |
| Depreciation & Amort. | $0.09B | $0.09B | $0.06B | $0.03B | $0.03B |
| Stock-Based Comp. | $0.02B | $0.03B | $0.02B | $0.05B | $0.07B |
| Change in Working Capital | $0.11B | ($0.01B) | $0.10B | ($0.07B) | ($0.06B) |
| Net Cash from Operations | ($0.11B) | ($0.73B) | ($0.65B) | ($0.60B) | ($0.61B) |
| Investing Activities | |||||
| Capital Expenditure | ($0.02B) | ($0.06B) | ($0.24B) | ($0.44B) | ($0.25B) |
| Purchases of Investments | ($0.05B) | $0.00B | ($0.13B) | ($1.78B) | ($2.17B) |
| Sales of Investments | $0.00B | $0.00B | $0.00B | $1.79B | $2.31B |
| Net Cash from Investing | ($0.36B) | $0.02B | ($0.38B) | ($0.47B) | ($0.11B) |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00B | ($0.01B) | ($0.03B) | ($0.03B) | $0.00B |
| Dividends Paid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Debt Issued / Repaid | ($0.15B) | ($0.01B) | $0.70B | $0.55B | $0.43B |
| Net Cash from Financing | $0.31B | $0.37B | $0.62B | $1.78B | $1.04B |
| Free Cash Flow | |||||
| Free Cash Flow | ($0.14B) | ($0.78B) | ($0.89B) | ($1.04B) | ($0.86B) |
| FCF Margin %(computed) | -13.83% | -352.69% | -424.81% | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-15 · CNY · B
Explore more Ascentage Pharma Group International data
About Ascentage Pharma Group International (AAPGV) Cash Flow Statement
Ascentage Pharma Group International generated operating cash flow of ($0.11B) and free cash flow of ($0.14B) for 2024 — a FCF margin of -13.83%. Capital expenditure was ($0.02B).
Frequently asked questions
AAPGV · 4 questionsAscentage Pharma Group International generated free cash flow of ($0.14B) for 2024, up 82.7% year-over-year.
AAPGV free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-15